Innoviva, Inc. (INVA)
23.02
+0.03
(+0.13%)
USD |
NASDAQ |
Apr 06, 16:00
23.20
+0.18
(+0.78%)
After-Hours: 07:04
Innoviva EPS Diluted (Quarterly) : 1.944 for Dec. 31, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Merck & Co., Inc. | 1.191 |
| Cytokinetics, Inc. | -1.495 |
| Nektar Therapeutics | -1.778 |
| Regeneron Pharmaceuticals, Inc. | 7.857 |
| Oramed Pharmaceuticals, Inc. | 0.2274 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 164.15M |
| Revenue (Quarterly) | 118.04M |
| Total Expenses (Quarterly) | -46.11M |
| Enterprise Value | 1.408B |
| Gross Profit Margin (Quarterly) | 64.05% |
| Earnings Yield | 13.26% |
| Operating Earnings Yield | 8.95% |
| Normalized Earnings Yield | 8.494 |